In a patient with early stage HR+ breast cancer who was perimenopausal at diagnosis but intolerant of AI, would you consider extending tamoxifen beyond 10 years?

ATLAS and aTTom trial : - 10 years of extended adjuvant Therapy.

In absence of data, I will not extend Adjuvant Therapy.

It depends upon the characteristics of primary breast cancer. For example, in the case of multi-node positivity, I would extend the duration to ten years total. In stage IA breast cancers, I generally don't extend the duration of anti-estrogen therapy.

In the case of intermediate or high-risk Oncoty...